论文部分内容阅读
目的观察玻璃体腔注射康柏西普治疗黄斑水肿的临床效果。方法 32例黄斑水肿患者随机均分为对照组和观察组。对照组常规行激光光凝治疗;观察组在对照组治疗的基础上增加康柏西普玻璃体腔内注射。观察两组患者治疗后临床疗效和并发症发生情况。结果观察组总有效率高于对照组(93.75%vs.75.00%)(P<0.05)。治疗6个月,观察组患眼黄斑中心凹视网膜厚度低于对照组[(227.36±30.27)μm vs.(263.25±28.69)μm](P<0.05)。观察组术后并发症发生率稍高于对照组(25.00%vs.18.75%)(P>0.05)。结论在常规行激光光凝治疗的基础上,玻璃体腔注射康柏西普能有效减轻黄斑水肿,改善患者视力。
Objective To observe the clinical effect of intravitreal injection of conbercip in the treatment of macular edema. Methods 32 patients with macular edema were randomly divided into control group and observation group. Control group routine laser photocoagulation treatment; observation group in the control group based on the increase of concomitant intravitreal injection. The clinical efficacy and complications of the two groups were observed after treatment. Results The total effective rate in observation group was higher than that in control group (93.75% vs. 75.00%) (P <0.05). After 6 months of treatment, the foveal retinaculum thickness in the observation group was lower than that in the control group [(227.36 ± 30.27) μm vs. (263.25 ± 28.69) μm] (P <0.05). The incidence of postoperative complications in observation group was slightly higher than that in control group (25.00% vs.18.75%) (P> 0.05). Conclusion Based on the conventional laser photocoagulation, intravitreal injection of conbaxip can effectively reduce macular edema and improve visual acuity.